Discontinue thienopyridine
PreclinicalSmall molecule
Discontinue thienopyridine is one of 5 small molecule programs targeting Antiplatelet. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Antiplatelet
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Colcrys
Jazz PharmaceuticalsApproved
Cysteine Hydrochloride
NovartisPhase 3
Discontinue thienopyridine
IIncheon St.Mary's Hospital
Preclinical
Antiplatelet Treatment
UUniversity of Calgary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Discontinue thienopyridine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIncheon St.Mary's Hospital